Charles Schwab Investment Management Inc Eiger Bio Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$0.55 - $1.26 $34,321 - $78,627	-62,403 Reduced 65.11%	33,436 $23,000
Q1 2023 May 11, 2023	SELL	$0.89 - $2.52 $14,664 - $41,522	-16,477 Reduced 14.67%	95,839 $86,000
Q4 2022 Feb 13, 2023	BUY	$1.02 - $7.48 $3,863 - $28,334	3,788 Added 3.49%	112,316 $132,000
Q3 2022 Nov 14, 2022	BUY	$6.04 - $9.66 $12,237 - $19,571	2,026 Added 1.9%	108,528 $818,000
Q2 2022 Aug 15, 2022	BUY	$4.99 - $8.96 $88,777 - $159,407	17,791 Added 20.06%	106,502 $671,000

Q1 2022 May 13, 2022	BUY	$3.84 - $9.74 $7,499 - $19,022	1,953 Added 2.25%	88,711 $737,000
Q3 2021 Nov 16, 2021	BUY	$6.68 - $9.1 $24,896 - $33,915	3,727 Added 4.49%	86,758 $580,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $9.23 $47,702 - $56,303	6,100 Added 7.93%	83,031 $708,000
Q1 2021 May 17, 2021	BUY	$8.44 - $12.66 $23,150 - $34,726	2,743 Added 3.7%	76,931 $681,000
Q4 2020 Feb 16, 2021	BUY	$7.98 - $12.29 $54,271 - $83,584	6,801 Added 10.09%	74,188 $912,000
Q3 2020 Nov 13, 2020	BUY	$7.96 - $12.42 $45,260 - $70,620	5,686 Added 9.22%	67,387 $549,000
Q2 2020 Aug 14, 2020	BUY	$5.4 - $13.37 $9,838 - $24,360	1,822 Added 3.04%	61,701 $593,000
Q1 2020 May 15, 2020	SELL	$4.91 - $14.7 $4,536 - $13,582	-924 Reduced 1.52%	59,879 $408,000
Q4 2019 Feb 07, 2020	BUY	$9.77 - $15.66 $72,718 - $116,557	7,443 Added 13.95%	60,803 $906,000
Q2 2019 Aug 09, 2019	BUY	$9.54 - $14.96 $509,054 - $798,265	53,360 New	53,360 $566,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $490M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.